Can I read Durvalumab vs. Atezolizumab in SCLC Treatment on EtoBox?

Durvalumab vs. Atezolizumab in SCLC Treatment by Duy Nguyễn is a document available to read on EtoBox.

What is Durvalumab vs. Atezolizumab in SCLC Treatment about?

This study compares the efficacy and safety of durvalumab plus chemotherapy versus atezolizumab plus chemotherapy in treating small-cell lung cancer (SCLC) in a real-world setting. Results indicate that durvalumab significantly improves median overall survival (22.0 months) compared to atezolizumab (10.0 months), with similar rates of immune-related adverse events between the two treatments. The addition of radiotherapy may enhance long-term survival but carries a risk of immune-related pneumonitis, warrant

Author

Duy Nguyễn

Language

EN